;0
6
0
0
Nausea
4
0
18
6
0
Stomatitis
0
1
0
3
0
Vomiting
4
0
0
0
0
Respiratory
Dyspnea
0
0
0
3
0
Rales
0
0
6
0
0
Rhinitis
0
0
6
0
0
Upper respiratory infection
0
3
0
0
0
CNS
Anxiety
0
0
0
0
4
Convulsions
0
0
0
3
0
Insomnia
0
1
0
0
0
Nervousness
0
0
0
0
4
Psychosis
4
0
0
0
0
Somnolence
0
1
6
0
0
Taste perversion
0
0
0
3
0
Cardiovascular
Atrial fibrillation
0
0
6
0
4
Atrial flutter
0
1
0
0
0
Cardiac failure
0
1
0
0
0
Hypertension
0
0
6
0
4
Syncope
0
0
6
0
0
Tachycardia
0
0
6
0
4
Endocrine
Hypothyroidism
0
0
6
0
0
Hemic and Lymphatic
Anemia
0
0
6
0
0
Leukopenia
4
0
0
0
0
Neutropenia
0
1
0
0
0
Thrombocytopenia
0
1
0
0
0
Musculoskeletal
Myalgia
0
1
0
0
0
Urogenital
Uremia
4
0
0
0
0
Laboratory Abnormalities
Hypocalcemia
0
1
12
0
0
Hypokalemia
4
4
18
0
0
Hypomagnesemia
4
10
12
3
4
Hypophosphatemia
0
9
18
3
0
Abnormal liver function
0
0
0
3
0
Paget’s Disease
Transient mild elevation of temperature >1°C above pretreatment baseline was noted within 48 hours after completion of treatment in 21% of the patients treatedwith 90 mg of pamidronate disodium in clinical trials.
Drug-related musculoskeletal pain and nervous system symptoms (dizziness, headache, paresthesia, increased sweating) were more common in patients with Paget’s disease treated with 90 mg of pamidronate disodi
